Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses the rapidly changing treatment landscape of chronic lymphocytic leukemia, including the development of new venetoclax-based combinations with improved treatment efficacy.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.